64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction

Opioid Use Disorder & The Modern Synthetic Opioid Era

The opioid overdose epidemic in North America has evolved through three distinct waves: prescription opioids (1990s), heroin resurgence (2010), and the current predominance of illicitly manufactured synthetic opioids, primarily fentanyl and its analogues (carfentanil, acetylfentanyl). Fentanyl is 50 to 100 times more potent than morphine, highly lipophilic, and rapidly permeates the central nervous system. Its high lipophilicity causes it to accumulate in adipose tissue with chronic use, prolonging its terminal elimination and significantly complicating standard buprenorphine induction protocols.

DSM-5 Diagnostic Criteria for Opioid Use Disorder (OUD)

OUD is defined by a problematic pattern of opioid use leading to clinically significant impairment or distress, manifested by at least 2 of 11 criteria over a 12-month period across four behavioral domains:

• Impaired Control: Using larger amounts or over longer periods than intended; persistent desire or unsuccessful efforts to cut down; spending excessive time obtaining, using, or recovering; intense craving.
• Social Impairment: Failure to fulfill major role obligations (work, school, home); continued use despite interpersonal problems; giving up important activities.
• Risky Use: Recurrent use in physically hazardous situations; continued use despite persistent physical or psychological harm.
• Pharmacological Adaptations: Tolerance and withdrawal.

                      DSM-5 SEVERITY STRATIFICATION FOR OUD

   Severity Staging      Criteria Count      Primary Care Clinical Implications
   ══════════════════════════════════════════════════════════════════════════════════════════════════════════
   Mild OUD              2 to 3 criteria     Initiate brief counseling, harm reduction, consider MOUD.
   ──────────────────────────────────────────────────────────────────────────────────────────────────────
   Moderate OUD          4 to 5 criteria     Strong indication for immediate MOUD (Buprenorphine or Methadone).
   ──────────────────────────────────────────────────────────────────────────────────────────────────────
   Severe OUD            ≥ 6 criteria        High risk of fatal overdose; urgent MOUD, wrap-around psychosocial care.
   ══════════════════════════════════════════════════════════════════════════════════════════════════════════

[!IMPORTANT] The Medical Supervision Exemption Rule Tolerance and withdrawal criteria DO NOT COUNT toward the diagnosis of OUD if the patient is taking opioid medications solely under appropriate medical supervision for chronic pain. An individual taking chronic prescribed opioids who exhibits physical dependence without loss of control, cravings, or functional impairment does not have OUD.

---

Medications for Opioid Use Disorder (MOUD)

Medications for Opioid Use Disorder (MOUD; formerly termed Medication-Assisted Treatment [MAT]) represent the definitive standard of care for moderate-to-severe OUD (Grade 1A recommendation). MOUD treatment:

• Reduces all-cause mortality by greater than 50%, primarily by slashing fatal overdose rates.
• Increases retention in addiction treatment programs.
• Drastically decreases illicit opioid consumption.
• Lowers criminal justice involvement.
• Decreases transmission of bloodborne pathogens, specifically HIV and Hepatitis C virus (HCV).

                     COMPARATIVE PHARMACOLOGY OF MOUD AGENTS

   Feature                 Buprenorphine / Naloxone        Methadone                       Extended-Release Naltrexone
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Receptor Activity       High-affinity PARTIAL           High-affinity FULL              High-affinity PURE
                           mu-opioid receptor agonist      mu-opioid receptor agonist      mu-opioid receptor ANTAGONIST
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Intrinsic Efficacy      Intermediate (~40–50%);         Full (100%); activates          Zero; blocks all receptor
                           exhibits ceiling effect         downstream signaling without    activation by endogenous
                           on respiratory depression       ceiling limit                   or exogenous opioids
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Formulation             Sublingual tablet / film        Oral liquid concentrate /       Intramuscular depot injection
                           (Suboxone; 4:1 ratio);          tablets (dispensed daily at     (Vivitrol 380 mg every
                           monthly SQ depot (Sublocade)    licensed OTP facilities)        4 weeks)
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Prescribing /           ANY clinician with standard     Restricted to federally         Any licensed clinician;
   Regulatory Status       Schedule III DEA registration   certified Opioid Treatment      no DEA schedule restriction
                           (X-WAIVER ELIMINATED)           Programs (42 CFR Part 8)        (non-controlled substance)
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Overdose Protection     Ceiling effect on respiratory   Risk of overdose during         No intrinsic overdose risk;
   Profile                 depression; safe in overdose    titration; additive toxicity    high fatal overdose risk if
                           unless mixed with sedatives     with other CNS depressants      patient lapses after washout
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Initiation Window       Requires active withdrawal      Can be initiated immediately;   Strict 7–10 day opioid-free
                           (COWS ≥ 8–12) to avoid          start low (20–30 mg) and        window (14 days for methadone/
                           precipitated withdrawal         titrate slowly over weeks       buprenorphine); negative UDS
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Safety / Monitoring     Minimal organ toxicity;         Baseline & periodic ECG for     Baseline liver function tests;
                           monitor baseline LFTs           QTc prolongation; CYP3A4        contraindicated in acute liver
                                                           drug-drug interactions          failure or active hepatitis
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

1. Buprenorphine (Suboxone, Subutex, Sublocade)

• Pharmacology: Buprenorphine is a partial mu-opioid receptor agonist with exceptionally high receptor binding affinity ($K_i \approx 0.2\text{ nM}$) and slow receptor dissociation kinetics, coupled with competitive antagonism at kappa-opioid receptors.
  • Partial Agonism: It satisfies mu-opioid receptors enough to suppress cravings and abolish withdrawal symptoms without producing euphoria in opioid-tolerant individuals.
  • Ceiling Effect: Its partial intrinsic activity creates a distinct ceiling effect on respiratory depression and euphoria at therapeutic doses ($>16\text{ mg/day}$). Unlike full agonists, increasing the buprenorphine dose does not proportionally increase respiratory depression, conferring an extraordinary safety profile.
• Suboxone Rationale (4:1 Buprenorphine:Naloxone Formulation):
  • Naloxone is added solely as an abuse deterrent against intravenous diversion.
  • When taken sublingually as prescribed, naloxone has virtually zero bioavailability ($<3%$) due to near-complete first-pass hepatic glucuronidation, allowing buprenorphine to exert its therapeutic effect unimpeded.
  • If the combination tablet or film is crushed and injected intravenously or snorted, naloxone reaches brain mu receptors with high bioavailability, immediately neutralizing opioid action and precipitating intense, agonizing withdrawal.
• Elimination of the Federal X-Waiver:
  • Under the Mainstreaming Addiction Treatment (MAT) Act passed by Congress in the Consolidated Appropriations Act of 2023, the historical requirement for clinicians to complete specialized training and apply for a federal DATA 2000 "X-waiver" was permanently eliminated.
  • Current Practice Standard: Any clinician (physician, nurse practitioner, physician assistant) with a standard DEA registration that includes Schedule III authority can prescribe buprenorphine for OUD without patient census caps or additional bureaucratic hurdles.

Clinical Management of Buprenorphine Induction

               MECHANISM OF BUPRENORPHINE-PRECIPITATED WITHDRAWAL

   [Scenario A: Full Agonist Occupancy]      [Scenario B: Buprenorphine Administered Too Early]
   
   Full Agonist (Heroin / Fentanyl)           Buprenorphine (Partial Agonist: High Affinity / Low Intrinsic)
   • High intrinsic activity (100%)          • Displaces full agonist from receptor
   • Maximum receptor activation             • Drops net receptor stimulation from 100% down to 40%
                                             ═══════════════════════════════════════════════════════════
                                             RESULT: ACUTE PRECIPITATED WITHDRAWAL COLLAPSE!

A. Standard Buprenorphine Induction

To avoid precipitating acute withdrawal, the patient must stop taking full-agonist opioids and wait until they enter objective mild-to-moderate withdrawal before the first buprenorphine dose is administered.

• Clinical Opiate Withdrawal Scale (COWS): Validated 11-item clinical scale scoring resting pulse rate, sweating, restlessness, pupil size, bone/joint aches, rhinorrhea/crying, GI upset, tremor, yawning, gooseflesh skin (piloerection), and anxiety/irritability.
• Induction Threshold: Patient must achieve a COWS score $\ge 8-12$ before taking buprenorphine.
  • Short-acting opioids (heroin, immediate-release oxycodone): Typically 12 to 24 hours after last use.
  • Long-acting opioids (methadone, sustained-release morphine): Typically 36 to 72 hours after last use.
  • Fentanyl: Highly variable due to tissue storage; often requires 24 to 48 hours or utilization of low-dose induction.
• Induction Dosing Protocol:
  • Day 1: Initial dose of 2 to 4 mg sublingual buprenorphine. Observe patient for 60 to 90 minutes. If withdrawal symptoms improve and no precipitation occurs, administer an additional 2 to 4 mg every 2 hours as needed (target total Day 1 dose: 8 to 12 mg).
  • Day 2 onwards: Titrate rapidly to a standard maintenance target dose of 16 to 24 mg daily (single daily dose or split twice daily). Doses above 24 mg daily provide minimal additional receptor saturation (receptor occupancy exceeds 90% at 16–24 mg) and are rarely indicated.

B. Low-Dose Buprenorphine Induction ("Micro-Dosing" / The Bernese Method)

In the synthetic fentanyl era, standard induction frequently triggers severe precipitated withdrawal or is rejected by patients who cannot tolerate reaching a COWS $\ge 8-12$. Low-dose induction introduces micro-doses of buprenorphine that slowly displace full agonists without precipitating acute withdrawal, while the patient continues taking their full-agonist opioid:

• Day 1: Buprenorphine 0.5 mg sublingual once daily; full-agonist continued as usual.
• Day 2: Buprenorphine 0.5 mg BID; full-agonist continued.
• Day 3: Buprenorphine 1 mg BID; full-agonist continued.
• Day 4: Buprenorphine 2 mg BID; full-agonist continued.
• Day 5: Buprenorphine 4 mg BID; full-agonist continued.
• Day 6: Buprenorphine 8 mg BID (16 mg/day); full-agonist continued.
• Day 7: Buprenorphine 16 mg daily; DISCONTINUE FULL-AGONIST OPIOID ENTIRELY.

2. Methadone Maintenance Therapy

• Pharmacology: Methadone is a synthetic, long-acting full mu-opioid receptor agonist with high oral bioavailability and a variable elimination half-life ranging from 24 to 36 hours (up to 60 hours in some individuals). It provides potent receptor stimulation, completely relieving cravings and preventing withdrawal.
• Federal Regulatory Framework (42 CFR Part 8): In the United States, outpatient methadone for the treatment of opioid use disorder CANNOT be prescribed by an office-based clinician or dispensed by a retail community pharmacy. It can be dispensed exclusively through federally certified and SAMHSA-regulated Opioid Treatment Programs (OTPs) under directly observed daily dosing protocols (with patients earning take-home doses based on stability and negative toxicology screens).
• Cardiovascular Toxicity & ECG Monitoring:
  • Methadone blocks cardiac human ether-à-go-go-related gene (hERG) potassium channels, producing dose-dependent prolongation of the corrected QT (QTc) interval and predisposing patients to life-threatening Torsades de Pointes.
  • Clinical Guidelines: Obtain a baseline ECG prior to methadone initiation. Repeat ECG at dose titration exceeding $100\text{ mg/day}$, or if patient has syncope, unheralded palpitations, or concurrent QT-prolonging medications (e.g., citalopram, azole antifungals, fluoroquinolones). If QTc is $>500\text{ ms}$, reduce methadone dose or transition to buprenorphine.
• Cytochrome P450 Drug Interactions: Methadone is extensively metabolized in the liver via CYP3A4, CYP2B6, and CYP2C19.
  • CYP Inducers (rifampin, carbamazepine, phenytoin, efavirenz): Dramatically increase methadone clearance, precipitating severe withdrawal.
  • CYP Inhibitors (fluconazole, clarithromycin, fluoxetine): Decrease clearance, triggering methadone accumulation and fatal overdose.

3. Extended-Release Injectable Naltrexone (Vivitrol)

• Pharmacology: Pure mu-opioid receptor antagonist administered as an intramuscular depot injection (380 mg) in the gluteal muscle every 4 weeks. Completely blocks opioid receptors, preventing any euphoric or analgesic response to exogenous opioids.
• The Obligate Washout Period: Administering naltrexone to a patient with active opioids in their system precipitates instantaneous, catastrophic withdrawal. Initiation requires:
  • Strict abstinence from short-acting opioids for at least 7 to 10 days.
  • Strict abstinence from long-acting opioids (methadone, buprenorphine) for at least 10 to 14 days.
  • Objective confirmation with a negative urine drug screen.
  • Performance of a Naloxone Challenge Test (0.4 to 0.8 mg IV or SC naloxone; verify no withdrawal signs for 30–60 minutes before administering depot naltrexone).
• Fatal Overdose Risk Upon Lapse: Chronic naltrexone therapy resets opioid tolerance to baseline (downregulating and resensitizing mu-opioid receptors). If a patient stops taking Vivitrol or attempts to override the receptor blockade by injecting massive doses of opioids, they are at catastrophic risk of fatal respiratory arrest from doses they previously tolerated.

---

Harm Reduction Frameworks & Overdose Prevention

Harm reduction encompasses evidence-based public health interventions designed to minimize the negative health, social, and legal consequences of drug use without mandating abstinence as a prerequisite.

1. Naloxone (Narcan) Overdose Rescue

• Mechanism: Pure, competitive mu-opioid receptor antagonist with high affinity that displaces opioids from receptors, rapidly reversing respiratory depression within 2 to 3 minutes.
• Formulations: Naloxone 4 mg intranasal spray (single pre-packaged device sprayed into one nostril; OTC status). Intramuscular autoinjector or 0.4 mg/mL vial for IM/SC injection.
• Administration Protocol: If an unresponsive individual exhibits signs of opioid overdose (pinpoint pupils, respiratory rate $<8-10\text{ breaths/min}$, cyanosis, snoring/gurgling respirations):
  1. Administer one 4 mg spray into one nostril.
  2. Call 911 immediately.
  3. If no response or inadequate spontaneous ventilation occurs after 2 to 3 minutes, administer a second 4 mg spray in the opposite nostril.
• The Half-Life Mismatch & Re-Narcotization:
  • Naloxone has an elimination half-life of 30 to 90 minutes.
  • Many synthetic opioids (fentanyl depots, methadone, extended-release oxycodone) have durations of action lasting 12 to 36 hours.
  • When naloxone wears off, residual circulating opioids can rebound onto receptors, causing re-narcotization and recurrent fatal respiratory depression. All patients revived with naloxone must be transported to an emergency department and observed for a minimum of 2 to 4 hours.
• Universal Co-Prescribing Guidelines: Clinicians must co-prescribe naloxone to:
  • All patients with a diagnosed opioid use disorder.
  • Any patient receiving chronic prescription opioid therapy at doses $\ge 50\text{ Morphine Milligram Equivalents (MME)/day}$.
  • Any patient receiving concomitant opioids and central nervous system depressants (e.g., benzodiazepines, z-drugs, gabapentinoids, sedating muscle relaxants).
  • Patients with past history of overdose, substance use treatment, or comorbid pulmonary/hepatic/renal disease.

2. Syringe Services Programs & Fentanyl Test Strips

• Syringe Services Programs (SSPs): Community-based programs providing access to sterile needles/syringes, safe disposal containers, and vaccination. SSPs reduce HIV and HCV incidence by over 50% and increase linkage to addiction treatment five-fold without increasing community crime or drug use rates.
• Fentanyl Test Strips (FTS): Lateral flow chromatographic strips that detect fentanyl and major analogues in drug samples dissolved in water, allowing individuals to identify contaminated supplies and adjust consumption behavior.
• Xylazine ("Tranq") Awareness: An alpha-2 adrenergic agonist approved exclusively for veterinary sedation that is increasingly co-adulterated into illicit synthetic fentanyl supplies.
  • Induces profound sedation, bradycardia, hypotension, and horrific necrotic skin ulcerations that appear at sites distant from injection points.
  • Critical Pearl: Xylazine is not an opioid; it is NOT reversed by naloxone! However, in any suspected overdose, naloxone must still be administered immediately to reverse the fentanyl component, followed by supportive airway and circulatory management.

---

Stimulant Use Disorders: Cocaine & Methamphetamine

Neurobiology & Systemic Complications

• Cocaine: Alkaloid that competitively blocks presynaptic reuptake transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT), producing profound synaptic monoamine accumulation. Also blocks voltage-gated sodium channels, conferring local anesthetic effects and arrhythmogenic cardiotoxicity.
• Methamphetamine: Synthetic phenylisopropylamine with potent, durable neurotoxicity. Unlike cocaine, methamphetamine not only blocks monoamine reuptake but also reverses vesicular monoamine transporter 2 (VMAT2) and DAT, actively pumping massive quantities of dopamine from storage vesicles directly into the synaptic cleft.
• Clinical Manifestations:
  • Neuropsychiatric: Intense euphoria followed by chronic paranoia, persecutory delusions, auditory/visual hallucinations, aggressive psychomotor agitation, and formication ("meth bugs")—delusional parasitosis causing severe, chronic skin-picking and infected neurotic excoriations.
  • Cardiovascular: Severe hyperadrenergic surges causing coronary vasospasm, accelerated atherosclerosis, acute myocardial infarction, aortic dissection, malignant hypertension, intracerebral hemorrhage, and dilated hyperadrenergic cardiomyopathy.
  • Oral Pathology ("Meth Mouth"): Rampant, severe dental caries, enamel erosion, and tooth loss. Caused by a confluence of drug-induced salivary gland hypoperfusion (severe xerostomia), prolonged bruxism/jaw-clenching, consumption of sugary beverages, and complete neglect of oral hygiene.

Evidence-Based Management of Stimulant Use Disorders

Unlike opioid use disorder, there are NO FDA-APPROVED MEDICATIONS for cocaine or methamphetamine use disorder.

• Contingency Management (CM): The undisputed gold standard treatment with the largest effect size in addiction medicine.
  • Rooted in operant conditioning: Patients earn immediate, tangible, escalating incentives (vouchers, gift cards, prize draws) contingent upon objective biological verification of drug abstinence (confirmed drug-negative urine screens).
  • Highly effective at inducing and sustaining stimulant abstinence and retaining patients in behavioral care.
• Community Reinforcement Approach (CRA) & CBT: Structured counseling identifying behavioral reinforcers in the patient's family, employment, and social environment to build an attractive drug-free lifestyle.
• Emerging Pharmacotherapy (The ADAPT-2 Trial):
  • The landmark ADAPT-2 randomized trial evaluated combination pharmacotherapy for moderate-to-severe methamphetamine use disorder:
  • Oral Bupropion XL 450 mg daily (dopamine/norepinephrine reuptake inhibitor that dampens withdrawal dysphoria and craving) PLUS Intramuscular Extended-Release Naltrexone 380 mg every 3 weeks (modulates endogenous opioid tone regulating dopamine release in the VTA).
  • Demonstrated modest but statistically significant improvements in verified methamphetamine-negative urine screens compared to placebo (13.6% vs 2.5%; number needed to treat [NNT] = 9). Currently used off-label in specialized addiction clinics.